Finerenone and empagliflozin combination versus each alone in chronic kidney disease with type 2 diabetes

Phase 2, randomised trial of finerenone and empagliflozin in chronic kidney disease (CKD) and type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Bayer. Primary endpoints: Mean ratio of change from baseline to Day 180 in UACR for combination therapy versus empagliflozin alone and Mean ratio of change from baseline to Day 180 in UACR for combination therapy versus finerenone alone. Started Aug 2022; status: completed.